Fairvalue-Calculator Fairvalue-Calculator
EN DE

Ovid Therapeutics Inc (OVID) Fair Value & Analysis

Healthcare · US · Market cap $432M

Price$2.32
Fair Value$3.15
Upside+35.8%
Quality95/100
Evidence: Low Range $2.36 – $3.94

Fair value as of: Jun 24, 2026

Analysis

Ovid Therapeutics Inc (OVID) currently trades at $2.32, while our model-based Fair Value estimate is $3.15 — implying the stock looks roughly 35.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Ovid Therapeutics Inc (OVID) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $3.15 versus a price of $2.32 — about +36% (undervalued). Model-based estimate, not financial advice.
What is the fair value of OVID?
Our 21-model fair value for Ovid Therapeutics Inc is $3.15 (as of Jun 24, 2026), built from audited fundamentals. The current price is $2.32.
What is the quality score of OVID?
Ovid Therapeutics Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.